AIRLINK 175.55 Decreased By ▼ -2.01 (-1.13%)
BOP 11.01 Decreased By ▼ -0.04 (-0.36%)
CNERGY 8.29 Increased By ▲ 0.12 (1.47%)
FCCL 47.23 Decreased By ▼ -0.09 (-0.19%)
FFL 16.02 Decreased By ▼ -0.10 (-0.62%)
FLYNG 27.31 Decreased By ▼ -0.04 (-0.15%)
HUBC 142.32 Decreased By ▼ -4.59 (-3.12%)
HUMNL 13.30 Decreased By ▼ -0.21 (-1.55%)
KEL 4.44 Decreased By ▼ -0.06 (-1.33%)
KOSM 5.90 Decreased By ▼ -0.01 (-0.17%)
MLCF 61.80 Decreased By ▼ -0.22 (-0.35%)
OGDC 226.77 Decreased By ▼ -7.91 (-3.37%)
PACE 5.77 Decreased By ▼ -0.03 (-0.52%)
PAEL 44.80 Decreased By ▼ -1.61 (-3.47%)
PIAHCLA 17.88 Decreased By ▼ -0.24 (-1.32%)
PIBTL 10.47 Decreased By ▼ -0.10 (-0.95%)
POWER 12.02 Increased By ▲ 0.03 (0.25%)
PPL 185.92 Decreased By ▼ -5.88 (-3.07%)
PRL 37.16 Decreased By ▼ -0.16 (-0.43%)
PTC 24.05 Increased By ▲ 0.85 (3.66%)
SEARL 100.29 Decreased By ▼ -0.60 (-0.59%)
SILK 1.15 No Change ▼ 0.00 (0%)
SSGC 38.51 Decreased By ▼ -1.20 (-3.02%)
SYM 14.75 Decreased By ▼ -0.28 (-1.86%)
TELE 7.73 Decreased By ▼ -0.11 (-1.4%)
TPLP 11.03 Decreased By ▼ -0.08 (-0.72%)
TRG 66.00 Decreased By ▼ -1.29 (-1.92%)
WAVESAPP 10.97 Decreased By ▼ -0.38 (-3.35%)
WTL 1.35 Decreased By ▼ -0.01 (-0.74%)
YOUW 3.78 Increased By ▲ 0.01 (0.27%)
BR100 12,826 Increased By 19.4 (0.15%)
BR30 38,861 Decreased By -842.2 (-2.12%)
KSE100 118,792 Decreased By -146.5 (-0.12%)
KSE30 36,779 Increased By 22.6 (0.06%)

ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) following detection of serious adverse implications owing to the use of unregistered/unavailable drugs in the country over the past few months has advised all the healthcare facilities to only import registered/enlisted drugs.

In an advisory released here on Monday, the DRAP said, “recently, adverse drug reactions (DARs) have been reported in a healthcare facility following the use of Avastin injections. Investigations have confirmed that these injections were falsified, and same has been endorsed by the maker authorization holder of the product i.e. M/S Roche Pakistan Limited”.

In September 2023, the DRAP launched an investigation after reports surged regarding the loss of vision in diabetic patients after using the aforementioned drug.

Now after over a year, DRAP completed the probe and keeping in view the findings of the investigation it said all the hospitals/healthcare facilities are required to procure registered/enlisted therapeutic goods exclusively through authorised distributors or sellers of the product.

DRAP said in case any therapeutic good is either unregistered or unavailable due to any reason, hospitals or health institutions can import such products by attaining permission of DRAP as per SRO 134 (I) 2021 dated 9 February 2021. Moreover, DRAP said that additional detailed guidance on the importation of unregistered or unavailable drugs for hospitals or institutional patients use can be found on official website of DRAP.

Furthermore, all adverse reactions experienced with the use of any product should be reported to the National Pharmacovigilance Centre (CPC) of DRAP, using adverse event reporting form which is also available on official DRAP website.

Copyright Business Recorder, 2024

Comments

Comments are closed.